Clobetasol Propionate Spray 0.05% for the Treatment of Moderate to Severe Plaque PsoriasisMENTER, Alan.Cutis (New York, NY). 2012, Vol 89, Num 2, pp 89-94, issn 0011-4162, 6 p.Article

New directions in the treatment of psoriasis, acne, and skin agingMENTER, Alan.Journal of the American Academy of Dermatology. 2000, Vol 43, Num 2, issn 0190-9622, 26 p., 3Conference Proceedings

The Status of Biologic Therapies in the Treatment of Moderate to Severe PsoriasisMENTER, Alan.Cutis (New York, NY). 2009, Vol 84, Num 4S, pp 14-24, issn 0011-4162, 11 p., SUPArticle

Psoriasis for the clinician: A new therapeutics era (the Biologics) beckonsMENTER, Alan.Journal of the American Academy of Dermatology. 2003, Vol 49, Num 2, issn 0190-9622, 107 p., SUPASerial Issue

The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapyMENTER, Alan.Journal of cutaneous medicine and surgery. 2004, Vol 8, pp 20-25, issn 1203-4754, 6 p., SUP2Article

Infliximab for psoriasisGOTTLIEB, Alice B.Journal of the American Academy of Dermatology. 2003, Vol 49, Num 2, pp S112-S117, issn 0190-9622, SUPAArticle

Combination azelaic acid therapy for acne vulgarisWEBSTER, G.Journal of the American Academy of Dermatology. 2000, Vol 43, Num 2, pp 47-50, issn 0190-9622, 3Conference Paper

Efalizumab: An overviewLEONARDI, Craig L.Journal of the American Academy of Dermatology. 2003, Vol 49, Num 2, pp S98-S104, issn 0190-9622, SUPAArticle

Tazarotene versus tretinoin or adapalene in the treatment of acne vulgarisKAKITA, L.Journal of the American Academy of Dermatology. 2000, Vol 43, Num 2, pp 51-54, issn 0190-9622, 3Conference Paper

Phototherapy treatment of psoriasis todayZANOLLI, Michael.Journal of the American Academy of Dermatology. 2003, Vol 49, Num 2, pp S78-S86, issn 0190-9622, SUPAArticle

Combining the new biologic agents with our current psoriasis armamentariumLEBWOHL, Mark.Journal of the American Academy of Dermatology. 2003, Vol 49, Num 2, pp S118-S124, issn 0190-9622, SUPAArticle

Evaluation and management of psoriatic arthritis: The role of biologic therapyRUDERMAN, Eric M.Journal of the American Academy of Dermatology. 2003, Vol 49, Num 2, pp S125-S132, issn 0190-9622, SUPAArticle

Pharmacokinetics and safety of tazaroteneMENTER, A.Journal of the American Academy of Dermatology. 2000, Vol 43, Num 2, pp 31-35, issn 0190-9622, 3Conference Paper

Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroidLEBWOHL, M.Journal of the American Academy of Dermatology. 2000, Vol 43, Num 2, pp 43-46, issn 0190-9622, 3Conference Paper

The design of clinical trials in psoriasis: Lessons for clinical practiceFELDMAN, Steven R.Journal of the American Academy of Dermatology. 2003, Vol 49, Num 2, pp S62-S65, issn 0190-9622, SUPAArticle

Tazarotene combination treatments in psoriasisGUENTHER, L.Journal of the American Academy of Dermatology. 2000, Vol 43, Num 2, pp 36-42, issn 0190-9622, 3Conference Paper

Topical Monotherapy With Clobetasol Propionate Spray 0.05% in the COBRA TrialMENTER, Alan.Cutis (New York, NY). 2007, Vol 80, Num 5, pp 12-19, issn 0011-4162, 8 p., SUPArticle

The use of cyclosporine in dermatology: Part IIRYAN, Caitriona; AMOR, Karrie T; MENTER, Alan et al.Journal of the American Academy of Dermatology. 2010, Vol 63, Num 6, pp 949-972, issn 0190-9622, 24 p.Article

The ethics of consulting with pharmaceutical companiesMINER, Andrew; MENTER, Alan.Clinics in dermatology. 2009, Vol 27, Num 4, pp 339-345, issn 0738-081X, 7 p.Article

Current and future management of psoriasisMENTER, Alan; GRIFFITHS, Christopher E. M.Lancet (British edition). 2007, Vol 370, Num 9583, pp 272-284, issn 0140-6736, 13 p.Article

Changing paradigms in dermatology: Nuclear hormone receptorsWINTERFIELD, Laura; CATHER, Jennifer; CATHER, John et al.Clinics in dermatology. 2003, Vol 21, Num 5, pp 447-454, issn 0738-081X, 8 p.Article

Development and use of alefacept to treat psoriasisKRUEGER, Gerald G; CALLIS, Kristina P.Journal of the American Academy of Dermatology. 2003, Vol 49, Num 2, pp S87-S97, issn 0190-9622, SUPAArticle

Integrating biologic therapies into a dermatology practice: Practical and economic considerationsCRAZE, Mark; YOUNG, Melodie.Journal of the American Academy of Dermatology. 2003, Vol 49, Num 2, pp S139-S142, issn 0190-9622, SUPAArticle

Cardiocutaneous syndromes and associationsABDELMALEK, Nagla F; GERBER, Terry L; MENTER, Alan et al.Journal of the American Academy of Dermatology. 2002, Vol 46, Num 2, pp 161-183, issn 0190-9622Article

Changing paradigms in dermatology: Tumor necrosis factor alpha (TNF-α) blockade in psoriasis and psoriatic arthritisVICTOR, Frank C; GOTTLIEB, Alice B; MENTER, Alan et al.Clinics in dermatology. 2003, Vol 21, Num 5, pp 392-397, issn 0738-081X, 6 p.Article